

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts
availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 13 DEC 01 ChemPort single article sales feature unavailable
NEWS 14 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 11:32:11 ON 16 DEC 2008

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY SESSION
0.21 0.21

FILE 'REGISTRY' ENTERED AT 11:32:22 ON 16 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 DEC 2008 HIGHEST RN 1084385-33-0
DICTIONARY FILE UPDATES: 14 DEC 2008 HIGHEST RN 1084385-33-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> E "DMXAA"/CN 25

```
E1      1      DMX 400YB40RBK/CN
E2      1      DMX 7R/CN
E3      1 -->  DMXAA/CN
E4      1      DMXAA SODIUM SALT/CN
E5      1      DMXAA-DICLOFENAC MIXTURE/CN
E6      1      DMXB-A/CN
E7      1      DMY PROTEIN (ORYZIAS CURVINOTUS GENE DMY)/CN
E8      1      DMZ/CN
E9      3      DN/CN
E10     1      DN (DISPERSANT)/CN
E11     1      DN (HUMAN PAPILLOMAVIRUS 35 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E12     1      DN (HUMAN PAPILLOMAVIRUS 39 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E13     1      DN (HUMAN PAPILLOMAVIRUS 44 GENE L1 244-NUCLEOTIDE FRAGMENT)/CN
E14     1      DN (HUMAN PAPILLOMAVIRUS 45 GENE L1 256-NUCLEOTIDE FRAGMENT)/CN
E15     1      DN (HUMAN PAPILLOMAVIRUS 51 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
E16     1      DN (HUMAN PAPILLOMAVIRUS 56 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
E17     1      DN (HUMAN PAPILLOMAVIRUS 59 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E18     1      DN (HUMAN PAPILLOMAVIRUS 66 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
E19     1      DN (HUMAN PAPILLOMAVIRUS 68 GENE L1 120-NUCLEOTIDE FRAGMENT)/CN
E20     1      DN (HUMAN PROTEIN SERINE/THREONINE KINASE GENE PLUS FLANKS)/CN
E21     1      DN (PESTICIDE)/CN
E22     2      DN 003/CN
E23     1      DN 0081/CN
E24     1      DN 02/CN
E25     1      DN 099/CN
```


=> S E3

L1 1 DMXAA/CN

=> DIS L1 1 SQIDE

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 117570-53-3 REGISTRY

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)
 OTHER NAMES:
 CN 5,6-Dimethyl-9-oxo-9H-xanthen-4-ylacetic acid
 CN 5,6-Dimethylxanthenone-4-acetic acid
 CN AS 1404
 CN DMXAA
 CN NSC 640488
 CN Vadimezan
 MF C17 H14 O4
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 DT.CA Caplus document type: Conference; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

184 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 184 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E "DMXAA"/CN 25
 E1 1 DMX 400YB40RBK/CN
 E2 1 DMX 7R/CN
 E3 1 --> DMXAA/CN
 E4 1 DMXAA SODIUM SALT/CN
 E5 1 DMXAA-DICLOFENAC MIXTURE/CN
 E6 1 DMXB-A/CN
 E7 1 DMY PROTEIN (ORYZIAS CURVINOTUS GENE DMY)/CN
 E8 1 DMZ/CN
 E9 3 DN/CN
 E10 1 DN (DISPERSANT)/CN
 E11 1 DN (HUMAN PAPILLOMAVIRUS 35 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
 E12 1 DN (HUMAN PAPILLOMAVIRUS 39 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
 E13 1 DN (HUMAN PAPILLOMAVIRUS 44 GENE L1 244-NUCLEOTIDE FRAGMENT)/CN

E14 1 DN (HUMAN PAPILLOMAVIRUS 45 GENE L1 256-NUCLEOTIDE FRAGMENT)/CN
 E15 1 DN (HUMAN PAPILLOMAVIRUS 51 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
 E16 1 DN (HUMAN PAPILLOMAVIRUS 56 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
 E17 1 DN (HUMAN PAPILLOMAVIRUS 59 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
 E18 1 DN (HUMAN PAPILLOMAVIRUS 66 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
 E19 1 DN (HUMAN PAPILLOMAVIRUS 68 GENE L1 120-NUCLEOTIDE FRAGMENT)/CN
 E20 1 DN (HUMAN PROTEIN SERINE/THREONINE KINASE GENE PLUS FLANKS)/CN
 E21 1 DN (PESTICIDE)/CN
 E22 2 DN 003/CN
 E23 1 DN 0081/CN
 E24 1 DN 02/CN
 E25 1 DN 099/CN

=> E "GEMCITABINE"/CN 25

E1 1 GEMCADIOL/CN
 E2 1 GEMCAT 200/CN
 E3 1 --> GEMCITABINE/CN
 E4 1 GEMCITABINE 5'-DIPHOSPHATE/CN
 E5 1 GEMCITABINE HYDROCHLORIDE/CN
 E6 1 GEMCITABINE TRIPHOSPHATE/CN
 E7 1 GEMCO/CN
 E8 1 GEMEDINE/CN
 E9 1 GEMEDIS/CN
 E10 1 GEMEPROST/CN
 E11 1 GEMETREL/CN
 E12 1 GEMEX/CN
 E13 1 GEMEX AGENT 03/CN
 E14 1 GEMFIBROZIL/CN
 E15 1 GEMFIBROZIL 1-O-B-D-GLUCURONIDE/CN
 E16 1 GEMFIBROZIL GLUCURONIDE/CN
 E17 1 GEMFIBROZIL POTASSIUM SALT/CN
 E18 1 GEMFIBROZIL SODIUM SALT/CN
 E19 1 GEMFIBROZIL-VITAMIN B6 MIXTURE/CN
 E20 1 GEMFLEX 1031C/CN
 E21 1 GEMFLEX 307/CN
 E22 1 GEMFLEX 409/CN
 E23 1 GEMGEL 100/CN
 E24 1 GEMGEL 100+/CN
 E25 1 GEMICALCONE A/CN

=> S E3

L2 1 GEMCITABINE/CN

=> DIS L2 1 SQIDE

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 95058-81-4 REGISTRY
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)
 OTHER NAMES:
 CN 2',2'-Difluoro-2'-deoxycytidine
 CN 2',2'-Difluorodeoxycytidine
 CN 2'-Deoxy-2',2'-difluorocytidine
 CN DDFC
 CN DFdC
 CN DFdCyd
 CN Folfugem
 CN Gemcitabine
 CN Gemcitabine
 CN LY 188011
 CN NSC 613327
 FS STEREOSEARCH
 MF C9 H11 F2 N3 O4


CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, HSDB*,
 IMSCOSEARCH, IMSDRUGNEWS, IMPATENTS, IMSPRODUCT, IMSRESEARCH, IPA,
 MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTLINE,
 TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic);
 RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
 study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP
 (Properties); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP
 (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in
 record)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
 study); FORM (Formation, nonpreparative); PREP (Preparation); PROC
 (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4347 REFERENCES IN FILE CA (1907 TO DATE)
 85 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 4373 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
15.22	15.43

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 11:33:33 ON 16 DEC 2008

FILE 'CAPLUS' ENTERED AT 11:33:33 ON 16 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:33:33 ON 16 DEC 2008

COPYRIGHT (C) 2008 THOMSON REUTERS




FILE 'USPATFULL' ENTERED AT 11:33:33 ON 16 DEC 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 11 and 12
L3 13 L1 AND L2
=> d 13 1-13 ibib, abs, hitstr

L3 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:1250046 CAPLUS
DOCUMENT NUMBER: 149:448110
TITLE: Preparation of Iso CA-4 and analogs as potent
cytotoxic agents and inhibitors of polymerization of
tubulin
INVENTOR(S): Alami, Mouad; Brion, Jean-Daniel; Provot, Olivier;
Peyrat, Jean-Francois; Messaoudi, Samir; Hamze,
Abdallah; Giraud, Anne; Bignon, Jerome; Bakala,
Joanna; Liu, Jian-Miao
PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique, Fr.
SOURCE: PCT Int. Appl., 78pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008122620	A1	20081016	WO 2008-EP54118	20080404
<p>W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
FR 2914640	A1	20081010	FR 2007-54280	20070404
PRIORITY APPLN. INFO.:			FR 2007-54280	A 20070404
OTHER SOURCE(S):			MARPAT 149:448110	
GI				




AB Isocombretastatin A-4 and analogs I [R1, R2, R3 = methoxy (possibly substituted by one or more fluorine atoms); R5 = R6 = hydrogen or fluorine; A = ring chosen from (un)substituted aryls and heteroaryls].
The process for the preparation of I comprises: (a) reaction of acetophenone


derivative II with an organometallic compound, A-M [M = alkali metal or earth alkaline metal substituted with a halogen]; and (b) reaction of the resulting phenylethanol derivative III with an acid to form I. Thus, Iso-CA-4 [I; A = C₆H₃OH-3-OMe-4, R₁ = R₂ = R₃ = OMe, R₄ = R₅ = R₆ = H (IV)] was prepared from 3,4,5-trimethoxyacetophenone (II; R₁ = R₂ = R₃ = OMe, R₄ = R₅ = R₆ = H) via reaction in PhMe with tert-butyl(5-lithio-2-methoxyphenoxy)dimethylsilane [prepared from tert-butyl(5-iodo-2-methoxyphenoxy)dimethylsilane via lithiation with Me₃CLi in hexane], dehydration of III with p-toluenesulfonic acid in CH₂Cl₂, and desilylation with K₂CO₃ in MeOH. The cytotoxic activity of IV was determined [IC₅₀ = 2-4 nM vs. HCT116; IC₅₀ = 5 nM vs. K562 cells; IC₅₀ = 2 nM vs. B16F10 cells; IC₅₀ = 8 nM vs. U87 cells; IC₅₀ = 8 nM vs. A549 cells; IC₅₀ = 4.5 nM vs. M435 cells; IC₅₀ = 4 nM vs. M231 cells; IC₅₀ = 2.2 μM vs tubulin polymerization].

IT 95058-81-4, Gemcitabine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination chemotherapy antitumor agent; iso CA-4 and analogs as
 powerful cytotoxic agents and inhibitors of tubulin polymerization)
 RN 95058-81-4 CAPLUS
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, DMXAA
 RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT
 (Reactant or reagent); USES (Uses)
 (reaction of, with iso CA-4 and aminodeoxy-iso-CA-4; iso CA-4 and
 analogs as powerful cytotoxic agents and inhibitors of tubulin
 polymerization)
 RN 117570-53-3 CAPLUS
 CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:473431 CAPLUS
 DOCUMENT NUMBER: 148:463206
 TITLE: oncolytic viruses and antiangiogenic agents in the
 treatment of cancer

INVENTOR(S): Karrasch, Matthias; Mescheder, Axel
 PATENT ASSIGNEE(S): Medigene AG, Germany
 SOURCE: PCT Int. Appl., 69pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008043576	A1	20080417	WO 2007-EP8930	20071015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NM, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-851598P P 20061013
 AB The invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy. Intraarterial infusions of oncolytic virus NV1020 to a patient with progressive metastatic colorectal adenocarcinoma followed by CPT-11 plus cetuximab resulted in stabilization of the disease at 6 mo post treatment.
 IT 117570-53-3, DMXAA
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (oncolytic viruses and antiangiogenic agents in treatment of cancer)
 RN 117570-53-3 CAPLUS
 CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



IT 95058-81-4, Gemcitabine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oncolytic viruses and antiangiogenic agents in treatment of cancer)
 RN 95058-81-4 CAPLUS
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:984120 CAPLUS

DOCUMENT NUMBER: 143:279360

TITLE: Methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor

INVENTOR(S): Penning, Maarten Tjerk; Van den Broek, Sebastiaan

Johannes Jacobus; Voest, Emile Eugene; Beerepoot,

Laurens Victor; Mehra, Niven

PATENT ASSIGNEE(S): Primagen Holding B. V., Neth.; UMC Utrecht Holding B. V.

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1571225	A1	20050907	EP 2004-75686	20040302
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CA 2558604	A1	20050909	CA 2005-2558604	20050302
EP 1725679	A1	20061129	EP 2005-710924	20050302
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20070077578	A1	20070405	US 2006-514345	20060831
PRIORITY APPLN. INFO.:			EP 2004-75686	A 20040302
			US 2004-549450P	P 20040302
			EP 2005-710924	A 20050302
			WO 2005-NL155	W 20050302

AB This invention provides methods of detecting CD133 antigen (AC133) expression level and use as a biomarker for human cancer diagnosis and therapy monitor. Blood anal. including number of circulating endothelial


cells and expression levels of human genes AC133 (CD133), EST032 and U1A evaluated by NASBA anal., were determined prior to and during chemotherapy using drugs such as angiostatin or PrimMed01, gemcitabine, and cisplatin, for a wide range of human tumor types. A use of a nucleic acid mol. comprising at least part of a sequence of AC133 or an analog thereof for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid mol.

IT 95058-81-4, Gemcitabine 117570-53-3, DMXAA
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor)
 RN 95058-81-4 CAPLUS
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 117570-53-3 CAPLUS
 CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2005:975665 CAPLUS
 DOCUMENT NUMBER: 143:264929
 TITLE: Methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases
 INVENTOR(S): Penning, Maarten Tjerk; Beerepoot, Laurens Victor; Van Den Broek, Sebastiaan Johannes Jacobus; Mehra, Niven; Voest, Emile Eugene
 PATENT ASSIGNEE(S): Primagen Holding B.V., Neth.; UMC Utrecht Holding B.V.
 SOURCE: Eur. Pat. Appl., 28 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

EP 1571225	A1	20050907	EP 2004-75686	20040302
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CA 2558604	A1	20050909	CA 2005-2558604	20050302
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1725679	A1	20061129	EP 2005-710924	20050302
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRIORITY APPLN. INFO.:			EP 2004-75686	A 20040302
			US 2004-549450P	P 20040302
			WO 2005-NL155	W 20050302
AB	The invention provides methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases. AC133 antigen mRNA may be quantitated by PCR, RT-PCR, NASBA, SDA, TMA, bDNA or rolling circle amplification. Diseases include cancer and heart disease, high blood pressure, ischemia, stroke, psoriasis, Crohn's disease, rheumatoid arthritis, endometriosis, atherosclerosis, obesity, diabetes mellitus, diabetic retinopathy, macular degeneration, Alzheimer's disease, Peutz Jegher's syndrome, multiple sclerosis, systemic lupus erythematosus, Wegener's granulomatosis, vasculitis, sickle cell disease, thalassemia and angina.			
IT	95058-81-4, Gemcitabine 117570-53-3 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases)			
RN	95058-81-4 CAPLUS			
CN	Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)			

Absolute stereochemistry. Rotation (+).



RN 117570-53-3 CAPLUS
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:202462 CAPLUS
 DOCUMENT NUMBER: 138:226761
 TITLE: Synergistic anticancer combinations containing 5,6-dimethylxanthenone-4-acetic acid
 INVENTOR(S): Wilson, William Robert; Siim, Bronwyn Gae
 PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020259	A2	20030313	WO 2002-GB4025	20020903
WO 2003020259	A3	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2458459	A1	20030313	CA 2002-2458459	20020903
AU 2002324143	A1	20030318	AU 2002-324143	20020903
AU 2002324143	B2	20070913		
EP 1423105	A2	20040602	EP 2002-758562	20020903
EP 1423105	B1	20081203		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012258	A	20041019	BR 2002-12258	20020903
JP 2005509599	T	20050414	JP 2003-524567	20020903
CN 1708296	A	20051214	CN 2002-817257	20020903
NZ 531045	A	20060831	NZ 2002-531045	20020903
EP 1759694	A2	20070307	EP 2006-77049	20020903
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI			
NZ 546573	A	20070531	NZ 2002-546573	20020903
CN 1994287	A	20070711	CN 2006-10151393	20020903
NZ 554093	A	20080731	NZ 2002-554093	20020903
NO 2004000591	A	20040430	NO 2004-591	20040210
ZA 2004001078	A	20050415	ZA 2004-1078	20040210
US 20040204480	A1	20041014	US 2004-790943	20040302

MX 2004PA02004	A	20050217	MX 2004-PA2004	20040302
IN 2004CN00684	A	20060113	IN 2004-CN684	20040402
US 20070060637	A1	20070315	US 2006-592678	20061103
AU 2007202083	A1	20070531	AU 2007-202083	20070509
US 20080070847	A1	20080320	US 2007-830650	20070730
US 20080070848	A1	20080320	US 2007-830659	20070730
US 20080070886	A1	20080320	US 2007-830668	20070730
US 20080070849	A1	20080320	US 2007-830677	20070730
PRIORITY APPLN. INFO.:			GB 2001-21285	A 20010903
			AU 2002-324143	A3 20020903
			CN 2002-817257	A3 20020903
			EP 2002-758562	A3 20020903
			WO 2002-GB4025	W 20020903
			US 2004-790943	A1 20040302


AB The present invention relates to synergistic combinations of the 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compds., Vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have antitumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compds. containing the combinations. The antitumor activity and host toxicity of DMXAA/cytotoxic drug combinations was assessed by varying the dose of chemotherapeutic drug up to the toxicity limit, with co-administration of a fixed DMXAA dose (80 μ mol/kg, ca. 80% of MTD), and evaluating subsequent tumor growth delay. Of the 7 drugs investigated, 4 (doxorubicin, 5-fluorouracil, cyclophosphamide and cisplatin) had appreciable activity against this tumor as indicated by dose-response relationships providing significant slopes by linear regression, and highly significant growth delays of 10 days at their MTDs.

IT 95058-81-4, Gemcitabine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (synergistic anticancer combinations)
 RN 95058-81-4 CAPLUS
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (synergistic anticancer combinations containing dimethylxanthenoneacetic acid)
 RN 117570-53-3 CAPLUS
 CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



L3 ANSWER 6 OF 13 USPATFULL on STN
 ACCESSION NUMBER: 2008:80755 USPATFULL
 TITLE: ANTI-CANCER COMBINATIONS
 INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND
 Sim, Bronwyn G., Auckland, NEW ZEALAND
 PATENT ASSIGNEE(S): CANCER RESEARCH TECHNOLOGY LIMITED, London, UNITED
 KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080070886	A1	20080320
APPLICATION INFO.:	US 2007-830668	A1	20070730 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JAECKLE FLEISCHMANN & MUGEL, LLP, 190 Linden Oaks, ROCHESTER, NY, 14625-2812, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1275	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 95058-81-4, Gemcitabine
 (synergistic anticancer combinations)
 RN 95058-81-4 USPATFULL
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
(synergistic anticancer combinations containing dimethylxanthenoneacetic acid)
RN 117570-53-3 USPATFULL
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



L3 ANSWER 7 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2008:80718 USPATFULL
TITLE: ANTI-CANCER COMBINATIONS
INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND
Siim, Bronwyn G., Mt. Eden, NEW ZEALAND
PATENT ASSIGNEE(S): CANCER RESEARCH TECHNOLOGY LIMITED, London, UK
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080070849	A1	20080320
APPLICATION INFO.:	US 2007-830677	A1	20070730 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JAECKLE FLEISCHMANN & MUGEL, LLP, 190 Linden Oaks, ROCHESTER, NY, 14625-2812, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1277	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity.

Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 95058-81-4, Gemcitabine

(synergistic anticancer combinations)

RN 95058-81-4 USPATFULL

CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid

(synergistic anticancer combinations containing dimethylxanthenoneacetic acid)

RN 117570-53-3 USPATFULL

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



L3 ANSWER 8 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2008:80717 USPATFULL

TITLE: ANTI-CANCER COMBINATIONS

INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND

Slim, Bronwyn G., Mt. Eden, NEW ZEALAND

PATENT ASSIGNEE(S): CANCER RESEARCH TECHNOLOGY LIMITED, London, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080070848	A1	20080320
APPLICATION INFO.:	US 2007-830659	A1	20070730 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING		

NUMBER

DATE

PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JAECKLE FLEISCHMANN & MUGEL, LLP, 190 Linden Oaks, ROCHESTER, NY, 14625-2812, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1276	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 95058-81-4, Gemcitabine

(synergistic anticancer combinations)

RN 95058-81-4 USPATFULL

CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid

(synergistic anticancer combinations containing dimethylxanthenoneacetic acid)

RN 117570-53-3 USPATFULL

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



L3 ANSWER 9 OF 13 USPATFULL on STN
 ACCESSION NUMBER: 2008:80716 USPATFULL
 TITLE: ANTI-CANCER COMBINATIONS
 INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND
 Siim, Bronwyn G., Mt. Eden, NEW ZEALAND
 PATENT ASSIGNEE(S): CANCER RESEARCH TECHNOLOGY LIMITED, London, UNITED
 KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080070847	A1	20080320
APPLICATION INFO.:	US 2007-830650	A1	20070730 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JAECKLE FLEISCHMANN & MUGEL, LLP, 190 Linden Oaks, ROCHESTER, NY, 14625-2812, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1275	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 95058-81-4, Gemcitabine
 (synergistic anticancer combinations)
 RN 95058-81-4 USPATFULL
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
 (synergistic anticancer combinations containing dimethylxanthenoneacetic acid)
 RN 117570-53-3 USPATFULL
 CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



L3 ANSWER 10 OF 13 USPATFULL on STN
 ACCESSION NUMBER: 2007:221355 USPATFULL
 TITLE: Method For Producing Fiber Composite Semi-Finished Products By Means Of A Round Braiding Technique
 INVENTOR(S): Gessler, Andreas, Haar, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): EADS DEUTSCHLAND GMBH, Ottobrunn, GERMANY, FEDERAL REPUBLIC OF, 85521 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070193439	A1	20070823
APPLICATION INFO.:	US 2005-592678	A1	20050406 (10)
	WO 2005-DE603		20050406
			20060913 PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-10200401731120040406	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300, US	

NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 3 Drawing Page(s)
 LINE COUNT: 289
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Method of producing fiber composite semifinished products by means of a circular braiding technique, a braiding core being braided with braiding threads which are unwound by means of bobbins circling concentrically about the braiding core in different directions, characterized in that the bobbins of one circling direction are fitted with reinforcing threads and the bobbins of the opposite circling direction are at least partially fitted with supporting threads, the supporting threads at least partially consisting of thermoplastic threads.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 95058-81-4, Gemcitabine
 (synergistic anticancer combinations)
 RN 95058-81-4 USPATFULL
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
(synergistic anticancer combinations containing dimethylxanthenoneacetic acid)
RN 117570-53-3 USPATFULL
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



L3 ANSWER 11 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2007:89005 USPATFULL
TITLE: Diagnosis of (a risk of) disease and monitoring of therapy
INVENTOR(S): Penning, Maarten Tjerk, Utrecht, NETHERLANDS
van den Broek, Sebastiaan Johannes Jacobus, Heerhugowaard, NETHERLANDS
Voest, Emile Eugene, Soest, NETHERLANDS
Beerepoot, Laurens Victor, Utrecht, NETHERLANDS
Mehra, Niven, Utrecht, NETHERLANDS
PATENT ASSIGNEE(S): PrimaGen Holding B.V., Amsterdam, NETHERLANDS (non-U.S. corporation)
UMC Utrecht Holding B.V., Utrecht, NETHERLANDS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070077578	A1	20070405
APPLICATION INFO.:	US 2006-514345	A1	20060831 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2005-NL155, filed on 2 Mar 2005, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-5710924	20040302
	US 2004-549450P	20040302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110, US	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 1272

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method for typing a sample of an individual suffering from, or at risk of suffering from, a disease and a method for monitoring treatment of an individual suffering from a disease comprising determining whether a sample from the individual comprises an expression product of AC133 in an amount that is indicative for the disease or for the treatment thereof. That amount is preferably quantified and compared with a reference value. In one aspect, the amount is compared with an amount of the expression product present in a sample that was obtained from the individual before treatment. Use of a nucleic acid molecule comprising at least part of a sequence of AC133, or an analogue thereof, for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 95058-81-4, Gemcitabine 117570-53-3

(methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases)

RN 95058-81-4 USPATFULL


CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 117570-53-3 USPATFULL

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



L3 ANSWER 12 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2007:69382 USPATFULL

TITLE: Anti-cancer combinations

INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND

Siim, Bronwyn G., Mt. Eden, NEW ZEALAND

PATENT ASSIGNEE(S): Cancer Research Technology Limited (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

-----	-----	-----
-------	-------	-------

PATENT INFORMATION: US 20070060637 A1 20070315
 APPLICATION INFO.: US 2006-592678 A1 20061103 (11)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1277	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6 -dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 95058-81-4, Gemcitabine
 (synergistic anticancer combinations)
 RN 95058-81-4 USPATFULL
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
 (synergistic anticancer combinations containing dimethylxanthenoneacetic acid)
 RN 117570-53-3 USPATFULL
 CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



L3 ANSWER 13 OF 13 USPATFULL on STN
 ACCESSION NUMBER: 2004:261978 USPATFULL
 TITLE: Anti-cancer combinations
 INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND
 Sium, Bronwyn G., Mt. Eden, NEW ZEALAND
 PATENT ASSIGNEE(S): Cancer Research Technology Limited (non-U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040204480	A1	20041014
APPLICATION INFO.:	US 2004-790943	A1	20040302 (10)


	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1297	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 95058-81-4, Gemcitabine
 (synergistic anticancer combinations)
 RN 95058-81-4 USPATFULL
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 117570-53-3, 5,6-Dimethylxanthenone-4-acetic acid
 (synergistic anticancer combinations containing dimethylxanthenoneacetic acid)
 RN 117570-53-3 USPATFULL
 CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 11:32:11 ON 16 DEC 2008)

FILE 'REGISTRY' ENTERED AT 11:32:22 ON 16 DEC 2008

E "DMXAA"/CN 25

L1 1 S E3

E "DMXAA"/CN 25

E "GEMCITABINE"/CN 25

L2 1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:33:33 ON 16 DEC 2008

L3 13 S L1 AND L2

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

84.86

100.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

STN INTERNATIONAL LOGOFF AT 11:35:02 ON 16 DEC 2008